Question 1

What dose of CBD is effective for anxiety?

Accepted Answer

Clinical trials demonstrating anxiolytic effects have used single doses of 300–600mg CBD. This is substantially higher than the 10–50mg found in most commercial CBD products. A 2019 RCT (Masataka, Frontiers in Psychology) found 300mg effective for social anxiety in a public speaking test. The 2011 Crippa et al. fMRI study used 400mg. Chronic dosing studies are limited — most evidence is from single-dose paradigms. The clinical relevance of low-dose commercial CBD for anxiety remains unestablished. For context, Epidiolex (FDA-approved CBD) is dosed at 5–20mg/kg/day for epilepsy, which translates to 350–1,400mg/day for a 70kg adult.

Question 2

How does THC reduce pain at the molecular level?

Accepted Answer

THC reduces pain through multiple mechanisms. Primary: partial agonism at CB1 receptors in the dorsal horn of the spinal cord inhibits nociceptive signal transmission by reducing presynaptic glutamate and substance P release. Secondary: CB1 activation in the periaqueductal gray (PAG) activates descending inhibitory pathways. Peripheral CB1 and CB2 receptors on nociceptors reduce peripheral sensitization. THC also activates TRPV1 channels (causing initial activation then desensitization) and modulates opioid receptor signaling. The analgesic effect is dose-dependent and subject to tolerance via CB1 receptor downregulation with chronic use.

Question 3

Why does cannabis suppress REM sleep, and does it matter?

Accepted Answer

THC suppresses REM sleep through CB1 receptor activation in the brainstem reticular formation, particularly the pedunculopontine tegmental (PPT) nucleus, which is critical for REM generation. This reduces both REM duration and density in a dose-dependent manner. Whether this matters clinically is debated. REM sleep is important for emotional memory consolidation and threat extinction — processes relevant to PTSD and anxiety. Chronic REM suppression in animal models impairs fear extinction learning. In humans, long-term heavy users show altered emotional processing. However, for patients whose sleep is severely disrupted by pain or PTSD nightmares, short-term REM suppression may be an acceptable trade-off. Rebound REM (vivid dreams, nightmares) occurs for 1–3 weeks after cessation.

Question 4

How does CBD reduce seizures — what are the mechanisms?

Accepted Answer

CBD's anticonvulsant mechanisms are distinct from its anxiolytic effects and involve multiple molecular targets: (1) GPR55 antagonism — GPR55 is a putative cannabinoid receptor whose activation promotes neuronal excitability; CBD blocks it. (2) TRPV1 desensitization — reduces neuronal hyperexcitability. (3) Voltage-gated sodium channel modulation — CBD inhibits persistent sodium currents that drive repetitive firing. (4) Adenosine reuptake inhibition — increases extracellular adenosine, which has anticonvulsant effects via A1 receptors. (5) Modulation of intracellular calcium signaling. Notably, CB1 receptor agonism does not appear to be the primary anticonvulsant mechanism, which is why CBD works without psychoactive effects. The relative contribution of each mechanism varies by seizure type.

Question 5

Can cannabis kill cancer cells? What does the research actually show?

Accepted Answer

Cannabinoids do kill cancer cells in laboratory settings — this is well-established in preclinical research. The mechanisms include: induction of apoptosis via ceramide synthesis and ER stress; inhibition of angiogenesis (tumor blood vessel formation); reduction of tumor cell migration and invasion; and autophagy induction. These effects have been demonstrated across glioblastoma, breast, prostate, colorectal, and lung cancer cell lines. However, three critical caveats apply: (1) The concentrations required (typically 5–20μM) are far higher than achievable in human plasma with any practical dosing regimen. (2) Some studies show paradoxical pro-tumor effects at lower, clinically relevant concentrations — particularly via CB2-mediated immunosuppression. (3) Zero human RCTs have demonstrated anti-tumor efficacy. The gap between cell-line results and human outcomes is enormous. Patients should not use cannabis as a cancer treatment or delay proven therapies based on this preclinical data.

Question 6

Which medications interact dangerously with CBD?

Accepted Answer

CBD is a potent inhibitor of CYP2C19 and CYP3A4 liver enzymes, and a moderate inhibitor of CYP2D6. The most clinically significant interactions: (1) Clobazam — CBD inhibits CYP2C19, increasing the active metabolite N-desmethylclobazam by 3–5x, causing sedation and respiratory depression. Dose reduction required. (2) Warfarin — CBD increases warfarin levels via CYP2C9 inhibition; INR can rise dangerously. Close monitoring required. (3) Tacrolimus and cyclosporine — immunosuppressant levels increase significantly; transplant rejection or toxicity risk. (4) Valproate — pharmacodynamic interaction causing elevated liver enzymes (additive hepatotoxicity). (5) Rifampin — a CYP inducer that dramatically reduces CBD levels. (6) Many antiepileptics, antidepressants, and antipsychotics are metabolized by these enzymes. Always consult a pharmacist before combining CBD with any prescription medication.

Question 7

Does cannabis use during adolescence cause permanent brain damage?

Accepted Answer

The evidence supports lasting — but not necessarily permanent — cognitive effects from heavy adolescent cannabis use. The Dunedin cohort study (Meier et al., PNAS 2012, n=1,037) found that persistent cannabis use starting before age 18 was associated with an 8-point IQ decline by age 38, not fully reversed by cessation. However, a Norwegian twin study suggested socioeconomic confounding. More recent neuroimaging studies show structural differences in prefrontal cortex, hippocampus, and amygdala in adolescent-onset heavy users. Mechanistically, the adolescent brain undergoes critical CB1 receptor-dependent synaptic pruning — THC disrupts this process. Key nuances: (1) Effects are dose-dependent — light/occasional use shows minimal long-term impairment. (2) Age of onset matters — before 16 is higher risk than 16–18. (3) "Permanent" is an overstatement for most users; significant recovery occurs with sustained abstinence. (4) Adult-onset heavy use shows much smaller cognitive effects.

Question 8

Why is oral CBD so poorly absorbed, and how can absorption be improved?

Accepted Answer

Oral CBD has only ~6% bioavailability due to extensive first-pass hepatic metabolism — primarily by CYP3A4 and CYP2C19 — and poor aqueous solubility (CBD is highly lipophilic, logP ~6.3). Most orally ingested CBD is metabolized to 7-hydroxy-CBD and 7-carboxy-CBD before reaching systemic circulation. Strategies to improve absorption: (1) High-fat meals — a high-fat meal increases CBD Cmax by ~5x and AUC by ~4x (FDA data from Epidiolex trials). (2) Sublingual administration — bypasses first-pass metabolism, achieving 35% higher Cmax with faster onset (~45 min vs. 2+ hours). (3) Lipid-based formulations — self-emulsifying drug delivery systems (SEDDS) improve solubilization. (4) Nanoformulations — nanoemulsions and liposomal CBD show improved bioavailability in early studies. (5) Inhalation — 10–35% bioavailability with rapid onset, but respiratory risks. For therapeutic use, sublingual or oral-with-fat is the most practical improvement over standard oral dosing.

Question 9

Does cannabis cause psychosis or schizophrenia?

Accepted Answer

Cannabis use is associated with increased risk of psychosis, but the relationship is complex and not simply causal. Key findings: (1) Meta-analyses find cannabis users have ~2x increased risk of psychotic disorders vs. non-users; daily high-potency (>10% THC) users have ~5x risk. (2) The association is dose-dependent — frequency, potency, and age of onset all matter. (3) Genetic vulnerability is critical — individuals with COMT Val158Met polymorphism or family history of psychosis are at substantially higher risk. (4) CBD appears to counteract THC-induced psychotomimetic effects — high-CBD strains are associated with lower psychosis risk than high-THC strains. (5) Causality vs. self-medication: some individuals with prodromal psychosis use cannabis to manage symptoms, inflating the association. The current scientific consensus (including NIDA and WHO) is that cannabis can precipitate psychosis in genetically vulnerable individuals and worsen outcomes in those with established schizophrenia, but does not cause schizophrenia in the general population.

Question 10

Is clinical endocannabinoid deficiency (CECD) a real condition?

Accepted Answer

Clinical endocannabinoid deficiency (CECD) is a hypothesis proposed by Dr. Ethan Russo (2004, 2016) suggesting that conditions like migraine, fibromyalgia, and IBS may result from deficient endocannabinoid tone. The hypothesis has biological plausibility: (1) Migraine patients show lower CSF anandamide levels than controls. (2) Fibromyalgia patients show altered CB1 receptor expression. (3) All three conditions respond to treatments that enhance endocannabinoid signaling. However, CECD is not an established medical diagnosis. The evidence is largely indirect and correlational. No validated biomarker exists for endocannabinoid deficiency. The hypothesis is scientifically interesting and has generated useful research questions, but should not be used to justify cannabis treatment for these conditions without direct clinical evidence. It remains a hypothesis, not a confirmed pathophysiological mechanism.

Question 11

What is the optimal THC:CBD ratio for medical use?

Accepted Answer

There is no single "optimal" ratio — the evidence suggests different ratios are appropriate for different conditions. What the research shows: (1) For cancer pain: balanced 1:1 THC:CBD (nabiximols/Sativex) outperforms THC-only in RCTs, with fewer adverse effects. The CBD appears to modulate THC's psychoactive effects via CB1 negative allosteric modulation. (2) For epilepsy: high-CBD, low-THC (Epidiolex is pure CBD). THC can actually lower seizure threshold in some epilepsy types. (3) For anxiety: high-CBD, low-THC. THC worsens anxiety at higher doses; CBD is anxiolytic. (4) For sleep onset: moderate THC may be more effective than CBD alone for acute sleep latency reduction. (5) For nausea: THC is the primary antiemetic; CBD adds limited benefit. The entourage effect hypothesis suggests whole-plant preparations may outperform isolates, but clinical evidence is limited. Practically, patients should start with high-CBD, low-THC ratios and titrate THC upward based on response and tolerability.

Question 12

Is cannabis safe to use during pregnancy?

Accepted Answer

No. Current evidence does not support cannabis use during pregnancy, and most medical organizations (ACOG, AAP, CDC) recommend complete abstinence. Key findings: (1) THC crosses the placenta and blood-brain barrier of the fetus. (2) CB1 receptors are expressed early in fetal neurodevelopment and play critical roles in neuronal migration and synaptogenesis. (3) Prenatal cannabis exposure is associated with lower birth weight, preterm birth, and increased NICU admission in multiple large cohort studies. (4) Longitudinal studies (Ottawa Prenatal Prospective Study, ABCD Study) show associations with cognitive deficits, attention problems, and increased anxiety in children exposed prenatally. (5) CBD is not established as safe in pregnancy — it is metabolized to THC in vivo and has not been studied in pregnant humans. The FDA explicitly warns against CBD use in pregnancy. The "morning sickness" use case is particularly concerning given the developmental vulnerability of early pregnancy.

Ask a Researcher

12 Questions